… tissue on demand for unmet medical needs methuselah foundation webinar june 10, 2009 private...
TRANSCRIPT
… tissue on demand for unmet medical needs
Methuselah Foundation WebinarJune 10, 2009Private Presentation
CONFIDENTIAL
This report is solely for the use of intended web audience. No part of it may be circulated, quoted, or reproduced for distribution without prior written approval from Organovo Inc.
Methuselah/Organovo Partnership
2
Angel investors
$
$$$$$
Investment Pool
Seed Funds
Return
Tissue Printing Is the First AutomatedTissue Manufacturing Process
Initial steps: adherent cells of interest are isolated or differentiated, preferably from an autologous source from patient (bone marrow, adipose tissue)
Spherical cell aggregate: the bioink
Supporting biocompatible gel: the biopaper
Organ printing: Building Organ Modules, by Borrowing from Nature
Fusion
Blood Vessel Contains Several Cell Types and Is Multilayered
After Printing, Blood Vessels Are Matured in Perfusion BioreactorsFor 6 Weeks to Assure Sufficient Strength of Extracellular Matrix
6
www.backpain-guide.com/.../10-1_Nerve_Struct.jpg
Fascicle
Nerve Structure
End to end repairLimit the stretching of the nerve to 10%
Autologous graftCan create
further trauma to the patient:•Donor site morbidity
•Aberrant regeneration•Inadequate return of
function
How to repair ruptured nerve?
Application to Nerve Regeneration
A Number of Attractive Commercial Areas Can Benefit EarlyFrom Organ Printing Technology
Vascular Health Presents Several Sets Of Large And Growing Opportunities For Medical Innovation
Dialysis access
Cardiac bypass
Leg Artery Grafts
Total US Opportunity = $2.4B
Source: HRI Global Medical Device Report, 2006 US Renal Data System 2007 Annual Data Report, Company Projections
100,000 leg bypasssurgeries year currently
450,000 cardiac bypasssurgeries year currently
100,000 new patients/year350,000 total patients
We Hear Clearly from Vascular Surgeons that they Want This Product
Market Leg Bypass; Dialysis Access
Primary Target Vascular Surgeons
Secondary Target Nephrologists
10
“Harvesting vein is by far the most invasive component of surgery;
provide an alternative that works better than plastics, and surgeons
will jump on it”-Cedars-Sinai Vascular Surgeon
“The big limit in surgery is the conduit we use – native vein is the best choice, but works poorly; and you face serious
wound issues with vein farming.”- Maine Vascular Surgeon
“We have become glorified plumbers. There is a constant need
to unblock current arteriovenous access grafts.”
-UCLA Interventional Radiologist
Organovo Blood Vessel Graft Has The Potential to Become Standard of Care
11
• Current grafts rapidly become blocked
• Require time and money to keep vessel open
• Unmet need for patient and payer
• Cost driver for payer to save $10-12k per revascularization
After 1 year After 3 years
Leg Vein 81% 69%
Synthetic Graft 66% 52%
Dialysis Graft 60% 20%
Success rates for current graft options
Rates given for below knee peripheral bypass except for dialysis graft. Source: W.L. Gore Co.
*Source:Cytograft public materials
Organovo Can Be Capital Efficient Like Our Competition andDifferentiate on Price and Improved Structure/Performance
Blood Vessel Structure
Improvement over current grafts
Price point target
Rolled fibroblast sheet Native artery structureThree layers of cells
$25k* $7-8k
Endothelial cells reduce clotting
Endothelial cells reduce clottingSmooth muscle cells allow elasticity
Manufacturing Process
Flat 2D tissue culture, manually rolled on dowel,
26 weeks*
Automated deposition and incubator maturation,
8 weeks
The Promise of Stem Cells Can Be Realized With Tissue Printing
13
100-200 companies
400-500 academic labs
1-2 companies
04/21/23
David Mooney, PhD – Harvard UniversityProfessor of BioengineeringCell signaling interactions
Gordana Vunjak-Novakovic, PhD – ColumbiaProfessor of Biomedical EngineeringCell culture for tissue engineering
Glenn Prestwich, PhD – University of UtahProfessor of ChemistryBiomaterials expertise Four biomedical companies launched
Craig Kent, MD – Chief of Surgery, Univ. WisconsinVascular SurgeonFormer Chairman, Society for Vascular Surgery
Advisory Board
Organovo’s Scientific Advisory Board Brings Togetherthe Expertise Required for Success
Dr. Craig Kent is Key Partner for Preclinical Studies
15
• University of Wisconsin, Madison
Chief of Surgery
Former Chairman, Society of Vascular Surgery
• Organovo SAB member
• NIH-funded preclinical lab, well published
Major Projects Underway
Vascular Graft Implantation
Patient Cell Sourcing
Organovo Is Actively Expanding Our Collaborations
16
